Orgenesis is a vertically-integrated biopharmaceutical company with unique expertise and experience in cell therapy development and manufacturing. The Company’s MaSTherCell subsidiary is a global Contract Development and Manufacturing Organization (CDMO). Through MaSTherCell, Orgenesis is able to deliver optimized process industrialization capacities to cell therapy companies, and speed up the arrival of these therapies onto the market. MaSTherCell’s customers include many of the world’s leading pharmaceutical and biotech companies, as well as research institutions and hospitals involved in cutting edge cell therapy. Orgenesis is also developing its own propriety cell therapies. Through its subsidiary Orgenesis Ltd,. Orgenesis is a pioneer in the process of Transdifferentiation (or cell reprograming), whereby an adult cell is converted into another type of cell, with its distinct phenotype and function. Orgenesis has utilized its proprietary technology/processes to successfully reprogram human liver cells into glucose-responsive, fully functional, insulin producing cells. Converting the diabetic patient's own tissue into insulin-producing cells has the potential to provide a practical cure for insulin dependent diabetes and overcome the significant issues of donor shortage, cost and exposure to chronic immunosuppressive therapy associated with islet cell transplantation.